On the fly News and insights, exclusive to thefly.com

QURE

uniQure

$61.20

2.65 (4.53%)

, SRPT

Sarepta

$121.54

2.23 (1.87%)

10:31
05/16/19
05/16
10:31
05/16/19
10:31

uniQure jumps after Chardan boosts price target to $175 from $100

Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease. The stock in morning trading is up 4.5%, or $2.63, to $61.64. uniQure, a Chardan Top Pick for 2019, could be headed towards a $5B-$10B valuation as support emerges for what could be a "best-in-class, breakthrough" Huntington's disease franchise, Amusa tells investors in a research note. In the second half of 2019, uniQure is expected to make AMT-130 the first one-time gene theraphy to enter the clinic for Huntington's, the analyst adds. Following due diligence, Amusa now expects peak AMT-130 sales of $2.7B, 25% risk-adjusted, in 2026. While the market opportunity for Huntington's is potentially larger than that for Duchenne muscular dystrophy, uniQure does have some analogy to Sarepta Therapeutics (SRPT), which moved up 114% in 2018, Amusa writes. He keeps a Buy rating on uniQure shares.

QURE

uniQure

$61.20

2.65 (4.53%)

SRPT

Sarepta

$121.54

2.23 (1.87%)

  • 06

    Jun

  • 19

    Aug

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.